Compare · MTSR vs NVO
MTSR vs NVO
Side-by-side comparison of Metsera Inc. (MTSR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTSR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $183.82B.
- Over the past year, MTSR is up 254.8% and NVO is down 34.2% - MTSR leads by 289.0 points.
- NVO has hit the wire 5 times in the past 4 weeks while MTSR has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for MTSR).
- Company
- Metsera Inc.
- Novo Nordisk A/S
- Price
- $70.53-0.32%
- $41.18+6.93%
- Market cap
- -
- $183.82B
- 1M return
- +33.65%
- +13.32%
- 1Y return
- +254.75%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 0
- 5
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MTSR
- SEC Form 15-12G filed by Metsera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.
- See Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)
- Director Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.
- SEC Form SCHEDULE 13G filed by Metsera Inc.
- CHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Berns Paul L returned 16,798,952 shares to the company, closing all direct ownership in the company (SEC Form 4)
- CHIEF MEDICAL OFFICER Marso Steven returned 17,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Large owner Population Health Partners Gp, Llc returned 12,767,462 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S